Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia.

Adult Humans Leukemia, Myeloid, Acute / diagnosis Middle Aged Mutation Prognosis Stem Cells Treatment Outcome

Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
03 2020
Historique:
received: 19 04 2019
accepted: 13 08 2019
pubmed: 16 8 2019
medline: 28 4 2021
entrez: 16 8 2019
Statut: ppublish

Résumé

Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understanding of the mutational patterns and the prognostic impact of molecular markers associated with stemness could lead to better clinical management and improve patients' outcomes. We applied a previously described 17-gene expression score comprising genes differently expressed between LSC and leukemic bulk blasts, for 934 adult patients with

Identifiants

DOI: 10.3324/haematol.2019.225003 PMID: 31413100 PMC: PMC7049376
pubmed: 31413100
pii: haematol.2019.225003
doi: 10.3324/haematol.2019.225003
pmc: PMC7049376
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

721-729

Subventions

Organisme : NCI NIH HHS
ID : U10 CA032291
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA035279
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA059518
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180850
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA101140
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA045450
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180867
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197734
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA003927
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180866
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140158
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180861
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233331
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233338
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright© 2020 Ferrata Storti Foundation.

Références

Leukemia. 2017 Oct;31(10):2211-2218
pubmed: 28321123
Int J Hematol. 2011 Aug;94(2):109-117
pubmed: 21800073
Leukemia. 2017 Jan;31(1):34-39
pubmed: 27624549
J Clin Oncol. 2013 Mar 1;31(7):923-9
pubmed: 23129738
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Blood Adv. 2017 Jan 24;1(5):331-340
pubmed: 29034366
Blood Adv. 2018 Dec 26;2(24):3608-3617
pubmed: 30567725
Blood. 2003 Apr 15;101(8):3142-9
pubmed: 12468427
Blood. 2008 Dec 15;112(13):4793-807
pubmed: 19064739
Leukemia. 2008 Aug;22(8):1539-41
pubmed: 18528419
J Clin Oncol. 2010 Aug 20;28(24):3890-8
pubmed: 20660833
Leukemia. 2018 Jun;32(6):1338-1348
pubmed: 29563537
J Clin Oncol. 1999 Dec;17(12):3767-75
pubmed: 10577848
Leukemia. 2013 Feb;27(2):482-5
pubmed: 22814295
Leukemia. 2015 Nov;29(11):2143-53
pubmed: 26055302
Leukemia. 2013 Oct;27(10):2023-31
pubmed: 23765227
Blood. 2010 Sep 2;116(9):1413-21
pubmed: 20522709
Hematol Oncol Clin North Am. 2011 Dec;25(6):1135-61, vii
pubmed: 22093581
J Clin Oncol. 2011 Apr 1;29(10):1364-72
pubmed: 21343560
Nature. 2017 Nov 16;551(7680):384-388
pubmed: 29144447
Cancer Res. 1998 Sep 15;58(18):4173-9
pubmed: 9751631
Blood. 2005 May 1;105(9):3420-7
pubmed: 15572587
J Clin Oncol. 2006 Aug 20;24(24):3904-11
pubmed: 16921041
Cancer Cell Int. 2007 Jun 04;7:9
pubmed: 17547749
Leukemia. 2019 Jul;33(7):1620-1634
pubmed: 30737482
Leukemia. 2013 Jan;27(1):82-91
pubmed: 23018865
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Leukemia. 2009 Jan;23(1):203-6
pubmed: 18596741
N Engl J Med. 1998 Dec 3;339(23):1649-56
pubmed: 9834301
N Engl J Med. 1995 Jun 22;332(25):1671-7
pubmed: 7760868
J Hematol Oncol. 2013 Nov 07;6(1):85
pubmed: 24517186
Blood. 2002 Dec 15;100(13):4325-36
pubmed: 12393746
Am J Hematol. 2017 Apr;92(4):388-396
pubmed: 28133783
J Clin Oncol. 2008 Oct 20;26(30):4934-9
pubmed: 18591543
Am J Hematol. 2012 Jan;87(1):89-99
pubmed: 22180162
J Clin Oncol. 1999 Sep;17(9):2831-9
pubmed: 10561359
Haematologica. 2012 Mar;97(3):388-92
pubmed: 22058207
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Blood. 2011 Dec 22;118(26):6920-9
pubmed: 22031865
N Engl J Med. 1994 Oct 6;331(14):896-903
pubmed: 8078551
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
J Clin Oncol. 2004 Nov 1;22(21):4290-301
pubmed: 15514371
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2012 Sep 1;30(25):3109-18
pubmed: 22753902
Blood. 1997 Feb 1;89(3):780-8
pubmed: 9028308
Nature. 2016 Dec 15;540(7633):433-437
pubmed: 27926740
J Clin Invest. 2011 Jan;121(1):384-95
pubmed: 21157036

Auteurs

Marius Bill (M)

The Ohio State University Comprehensive Cancer Center, Columbus, OH marius.bill@osumc.edu.

Deedra Nicolet (D)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Jessica Kohlschmidt (J)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Christopher J Walker (CJ)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Krzysztof Mrózek (K)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Ann-Kathrin Eisfeld (AK)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Dimitrios Papaioannou (D)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Xiaoqing Rong-Mullins (X)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Zachary Brannan (Z)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Jonathan E Kolitz (JE)

Monter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY.

Bayard L Powell (BL)

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.

Kellie J Archer (KJ)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
College of Public Health, The Ohio State University, Columbus, OH.

Adrienne M Dorrance (AM)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Andrew J Carroll (AJ)

Department of Genetics, University of Alabama at Birmingham, Birmingham, AL.

Richard M Stone (RM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

John C Byrd (JC)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Ramiro Garzon (R)

The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Clara D Bloomfield (CD)

The Ohio State University Comprehensive Cancer Center, Columbus, OH clara.bloomfield@osumc.edu.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Diagnostic › Pronostic › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Cellules › Cellules souches › Mutations associated with a 17-gene leukemia...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Mutations associated with a 17-gene leukemia...